Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof

Patent metadata

Field	Value
Publication number	US-9884017-B2
Application number	US-201715639114-A
Country	US
Kind code	B2
Filing date	Jun 30, 2017
Priority date	Apr 28, 2009
Publication date	Feb 6, 2018
Grant date	Feb 6, 2018

Abstract

The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.

First claim

What is claimed is:

1. A foamable composition formulated for skin delivery of an active agent comprising:
a minocycline in a therapeutically effective amount of about 1 to about 5% by weight of the composition;
a short chain alcohol comprising ethanol;
about 12% to about 30% by weight of the composition of a protic polar solvent comprising propylene glycol;
a polymeric agent comprising a cellulose ether;
a modulating agent comprises an antioxidizing agent;
a metal;
an essential oil;
wherein the foamable composition is surfactant free;
and wherein the composition is waterless and essentially free of fatty alcohol.

2. The foamable composition according to claim 1 , wherein the minocycline is a minocycline hydrochloride.

3. The foamable composition according to claim 1 , wherein the therapeutically effective amount is about 1%.

4. The foamable composition according to claim 1 , wherein the therapeutically effective amount is about 4%.

5. The foamable composition according to claim 1 , wherein the short chain alcohol is present in an amount of at least 55% by weight of the composition.

6. The foamable composition according to claim 1 , wherein the cellulose ether is a hydroxypropyl cellulose.

7. The foamable composition according to claim 1 , wherein the modulating agent is present in an amount ranging from about 0.1% to about 10% by weight of the composition.

8. The foamable composition according to claim 7 , wherein the modulating agent is present in an amount ranging from about 1% to about 5% by weight of the composition.

9. The foamable composition according to claim 1 , wherein the cellulose ether is present in an amount ranging from about 0.5% to about 1% by weight of the composition.

10. The foamable composition according to claim 1 , wherein:
the minocycline is minocycline hydrochloride; and
the cellulose ether is a hydroxypropyl cellulose.

11. The foamable composition according to claim 10 , wherein:
the ethanol is present in an amount of at least 55% by weight of the composition;
the hydroxypropyl cellulose is present in an amount of about 0.5% to about 1% by weight of the composition; and
the modulating agent is present in an amount ranging from about 0.1% to about 10% by weight of the composition.

12. The foamable composition according to claim 11 , wherein the therapeutically effective amount is about 1% by weight of the composition.

13. The foamable composition according to claim 11 , wherein the therapeutically effective amount is about 4% by weight of the composition.

14. The foamable composition according to claim 1 , wherein the liquefied or compressed gas propellant is present in an amount ranging from about 3% to about 25% by weight of the composition.

Assignees

• Foamix Pharmaceuticals Ltd

Inventors

• Tamarkin Dov
• Schuz David
• Berman Tal
• Hazot Yohan

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61K47/38

  Cellulose; Derivatives thereof · CPC title

• A61Q19/00

  Preparations for care of the skin · CPC title

• A61K47/14

  Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title